Commission on Cancer Oncology Lecture: Pancreatic Cancer: Progress and Prospects (No CME)
Pancreatic Cancer: Progress and Prospects
Presiding Officer and Introducer: Heidi Nelson, MD, FACS, Rochester, MN
Lecturer: Andrew L. Warshaw, MD, FACS, Boston, MA
Pancreatic cancer is the third-leading cause of cancer-related death in the U.S. and is on track to become number two in 2020, surpassing colorectal cancer. Outcomes have not improved substantially in 40 years, with just a 9 percent five-year survival rate today versus 5 percent in the late 1970s. However, a combination of new approaches is transforming the treatment and survival of pancreatic cancer patients.
Andrew L. Warshaw, MD, FACS, FRCSEd(Hon), discussed advances in pancreatic cancer treatment during the Commission on Cancer Oncology Lecture, Pancreatic Cancer: Progress and Prospects. A Past-President of the American College of Surgeons, Dr. Warshaw is senior consultant, international and regional clinical relations, Massachusetts General Hospital, and the W. Gerald Austen Distinguished Professor of Surgery, Harvard Medical School, Boston.
The Commission on Cancer Oncology Lecture was established in 1988 to explore major developments in oncology and to focus on the surgeon's role in caring for cancer patients.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures).
Faculty and Disclosures
Heidi Nelson, MD, FACS - Nothing to Disclose
Andrew L. Warshaw, MD, FACS - ORDx+Rx, Solutions for Surgical Safety: Consulting Fee: Partner, Consultant
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - Nothing to Disclosure
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - Nothing to Disclosure
David C. Borgstrom, MD, FACS, Morgantown, WV - Nothing to Disclosure
Daniel L. Dent, MD, FACS, San Antonio, TX - Nothing to Disclosure
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Cynthia D. Downard, MD, FACS, Louisville, KY - Nothing to Disclosure
Audra A. Duncan, MD, FACS, London, ON - Nothing to Disclosure
Mariam F. Eskander, MD, Boston, MA - Nothing to Disclosure
Paula Ferrada, MD, FACS, Richmond, VA - Nothing to Disclosure
Neil H. Hyman, MD, FACS, Chicago, IL - Nothing to Disclosure
Martin S. Karpeh, Jr., MD, FACS, New York, NY - Nothing to Disclosure
Dennis H. Kraus, MD, FACS, New York, NY - Nothing to Disclosure
Kenneth W. Sharp, MD, FACS, Nashville, TN - Nothing to Disclosure
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - Nothing to Disclosure
Edith Tzeng, MD, FACS, Pittsburgh, PA - Nothing to Disclosure
Barbara Lee Bass, MD, FACS, FRCSEng(Hon), FRCSI(Hon), FCOSECSA(Hon), Houston, TX - Nothing to Disclosure
Quan-Yang Duh, MD, FACS, San Francisco, CA - Nothing to Disclosure
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - Nothing to Disclosure
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - Nothing to Disclosure
A Certificate of Completion will be awarded.
This educational activity is not eligible for CME or CE credits.